Medicaroid Obtains CE Marking Under the MDR for the hinotoriTM Surgical Robot System

Medicaroid Corporation (HQ: Kobe, Japan; Board Director, CEO and President Koji Muneto) announced that the CE marking under the Medical Device Regulation (MDR(2017/745)) has been obtained for the hinotori™ Surgical Robot System (hereinafter referred to as “the hinotori™”).

The hinotori™ was originally approved for manufacturing and marketing in Japan in 2020 and subsequently launched domestically. It thereafter received regulatory approvals in Singapore in 2023 and Malaysia in 2024, and has been introduced at medical institutions across these regions. To further support its expansion in the Asia-Pacific region, it received regulatory approval in Vietnam in 2026. In parallel with advancing the business in Japan and the Asia-Pacific region, Medicaroid has been preparing for expansion into Europe, the Middle East, and Africa (EMEA). To support this initiative, Medicaroid Europe GmbH was established in Germany in 2020 as a base of operations. With the acquisition of CE marking, Medicaroid is now able to market the hinotori™ in EU member states as well as certain non-EU countries. Entry into the European market represents a significant milestone for Medicaroid in continuing to contribute to global healthcare through medical robots.

Medicaroid remains dedicated to supporting a thriving society where patients, their families, and healthcare professionals can live healthier, more peaceful lives.